UBS reiterates its 'neutral' rating onOSI Pharmaceuticals Inc (Nasdaq: OSIP) and cuts its price target from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE